

INVENTORS: Piechaczyk & Noel  
UNITED STATES  
NATIONAL PHASE  
OF PCT  
INTERNATIONAL  
APPLICATION NO.: PCT/FR98/0081

Sub B1  
amount of this antibody or a fragment of it, by cells of said mammal genetically modified by said nucleic acid sequence and not naturally producing antibodies.

AI  
CONT  
2. (Amended) Biological material according to claim 1, characterized by the fact that it includes a nucleic acid sequence containing an antibody gene and elements for expressing *in vivo* said antibody gene and the secretion in the blood circulation of a mammal of a therapeutically effective amount of this antibody or a fragment of it, by cells of said mammal genetically modified by said nucleic acid sequence and not naturally producing antibodies. [This sequence is in the form of a virgin DNA or RNA sequence.]

OR  
9. (Amended) Biological material according to [any of the preceding claims] claim 1, characterized by the fact that the cells not naturally producing antibodies are selected from those which have:

- the ability to be able to secrete proteins in the blood circulation of a mammal;
- a long life in the mammal's organism.

Sub B3  
11. (Amended) Biological material according to [any of claims 9 and 10] claim 9, characterized by the fact that the cells not naturally producing antibodies are selected from keratinocytes, hepatocytes, skin fibroblasts, myoblasts, endothelial cells and hematopoietic stem cells.

12. (Amended) Biological material according to [any of the preceding claims] claim 1, characterized by the fact that the antibody gene is a gene coding for a virgin antibody, fragment or derivative of this antibody such as a chimerical antibody.

INVENTORS: Piechaczyk & Noel  
UNITED STATES  
NATIONAL PHASE  
OF PCT  
INTERNATIONAL  
APPLICATION NO.: PCT/FR98/0081

2635  
A4  
15. (Amended) Pharmaceutical composition comprised of a biological material according to [any of claims 1 to 14] claim 1 preferably associated with a pharmaceutically acceptable vehicle.

17. (Amended) Use of a biological material according to [any of claims 1 to 14] claim 1 or cells according to claim 16, for the preparation of a pharmaceutical composition for the treatment of cancer or viral infections.

#### REMARKS

Applicants have amended claims 1 and 2 to the form of single sentences. Applicants have amended claims 9, 11, 12, 15, and 17 to remove multiple dependencies. No new matter is added.